Global GLP-1 Agonists Market to Grow at a CAGR of 26.5% Through 2032
According to a newly published market research report by 24LifeSciences, global Glucagon Like Peptide-1 (GLP-1) Agonists market was valued at USD 75.95 billion in 2024 and is projected to reach USD 404.1 billion by 2031, growing at a compound annual growth rate (CAGR) of 26.5% during the forecast period.
Glucagon-like peptide-1 (GLP-1) receptor agonists are a revolutionary class of injectable and oral medications that mimic the action of the endogenous incretin hormone GLP-1. These advanced therapeutics are primarily prescribed for the management of type 2 diabetes due to their ability to stimulate insulin secretion in a glucose-dependent manner, significantly reducing the risk of dangerous hypoglycemic events compared to older insulin secretagogues. Their profound efficacy in weight management and demonstrated cardiovascular risk reduction have fundamentally expanded their role in modern metabolic care, positioning them as one of the most significant drug classes in contemporary medicine.
Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/6560/glucagon-like-peptide-glp-agonists-market-market
According to a newly published market research report by 24LifeSciences, global Glucagon Like Peptide-1 (GLP-1) Agonists market was valued at USD 75.95 billion in 2024 and is projected to reach USD 404.1 billion by 2031, growing at a compound annual growth rate (CAGR) of 26.5% during the forecast period.
Glucagon-like peptide-1 (GLP-1) receptor agonists are a revolutionary class of injectable and oral medications that mimic the action of the endogenous incretin hormone GLP-1. These advanced therapeutics are primarily prescribed for the management of type 2 diabetes due to their ability to stimulate insulin secretion in a glucose-dependent manner, significantly reducing the risk of dangerous hypoglycemic events compared to older insulin secretagogues. Their profound efficacy in weight management and demonstrated cardiovascular risk reduction have fundamentally expanded their role in modern metabolic care, positioning them as one of the most significant drug classes in contemporary medicine.
Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/6560/glucagon-like-peptide-glp-agonists-market-market
Global GLP-1 Agonists Market to Grow at a CAGR of 26.5% Through 2032 According to a newly published market research report by 24LifeSciences, global Glucagon Like Peptide-1 (GLP-1) Agonists market was valued at USD 75.95 billion in 2024 and is projected to reach USD 404.1 billion by 2031, growing at a compound annual growth rate (CAGR) of 26.5% during the forecast period. Glucagon-like peptide-1 (GLP-1) receptor agonists are a revolutionary class of injectable and oral medications that mimic the action of the endogenous incretin hormone GLP-1. These advanced therapeutics are primarily prescribed for the management of type 2 diabetes due to their ability to stimulate insulin secretion in a glucose-dependent manner, significantly reducing the risk of dangerous hypoglycemic events compared to older insulin secretagogues. Their profound efficacy in weight management and demonstrated cardiovascular risk reduction have fundamentally expanded their role in modern metabolic care, positioning them as one of the most significant drug classes in contemporary medicine. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/6560/glucagon-like-peptide-glp-agonists-market-market
0 Comments 0 Shares